Acquired 4 targeted therapies including TIGIT antibody and Gilead to expand its oncology pipeline for US$725 million

Today, Gilead Sciences and Arcus Biosciences jointly announced that Gilead has exercised its option to obtain multiple R&D projects in Arcus’ clinical R&D pipeline, including two monoclonal antibodies domvanalimab and AB308 that target TIGIT, and small Molecular therapy etrumadenant and quemliclustat

Gilead and Arcus reached a 10-year partnership in May last year to jointly develop drugs under development in Arcus' R&D pipeline

▲The mechanism by which TIGIT regulates the immune response of T cells (picture source: reference [1])

Domvanalimab (AB154) is an anti-TIGIT antibody that removes the Fc-terminal function of the antibody.

▲Introduction of Domvanalimab and AB308 (picture source: Arcus official website)

Etrumadenant is an adenosine A2a/A2b dual receptor antagonist for the treatment of NSCLC, colon cancer and prostate cancer.

Image source: Arcus official website

Quemliclustat is a small molecule CD73 inhibitor for the treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) and is in phase 1 clinical trials

By obtaining these clinical development projects, Gilead and Arcus can accelerate the clinical development of drugs and promote the exploration of combination therapies

According to the agreement between the two parties, Arcus will receive a total of US$725 million in payments

Reference materials:

[1] Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration.

[2] ASCO 20 Roche Analyst Event.